The 59 references in paper A. Zemchenkov Y., R. Gerasimchuk P., K. Novokshonv Y., Y. Karelina V., Y. Fedotov N., R. Chernikov A., I. Sleptsov V., A. Semenov A., A. Bubnov N., Александр Земченков Юрьевич, Роман Герасимчук Павлович, Константин Новокшонов Юрьевич, Юлия Карелина Валерьевна, Юрий Федотов Николаевич, Роман Черников Анатольевич, Илья Слепцов Валерьевич, А. Семенов А., Александр Бубнов Николаевич (2016) “Сравнительный анализ эффективности паратиреоидэктомии и местных инъекций активаторов рецепторов витамина D в паращитовидные железы // Comparative analysis of the parathyroidectomy and local vitamin D receptor activator injections into parathyroid glands” / spz:neicon:nefr:y:2016:i:4:p:80-92

1
Ketteler M, Elder GJ, Evenepoel P et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int
(check this in PDF content)
2
15;87(3):502-528. doi: 10.1038/ki.2014.425 2. Ермоленко ВМ, Волгина ГВ, Добронравов ВА и соавт. Национальные рекомендации по минеральным и костным нарушениям при хронической болезни почек. Нефрология и диализ 2011; 13(1): 33-51 [Ermolenko VM, Volgina GV, Dobronravov VA et al. National recommendations on CKD-MBD. Nephrology and Dialysis (in Rus) 2011; 13(1):33-51]
(check this in PDF content)
3
Cattinelli I, Bolzoni E, Barbieri C et al. Use of Self Organizing Maps for Balanced Scorecard analysis to monitor the performance of dialysis clinic chains. Health Care Manag Sci 2012; 15(1): 79-90. doi: 10.1007/s10729-011-9183-6
(check this in PDF content)
4
Андрусев АМ, Бевзенко АЮ, Вишневский КА и др. Рекомендации российского диализного общества по оценке качества оказания медицинской помощи при подготовке к началу заместительной почечной терапии и проведении лечения диализными методами взрослых пациентов с ХБП V стадии. Нефрология и диализ 2015;17(1):10-19 [Rekomendatcii rossii`skogo dializnogo obshchestva po ocenke kachestva okazaniia meditcinskoi` pomoshchi pri podgotovke k nachalu zamestitel`noi` pochechnoi` terapii i provedenii lecheniia dializny`mi metodami vzrosly`kh patcientov s KHBP V stadii. Nephrology and Dialysis (in Rus) 2015;17(1):10-19
(check this in PDF content)
5
Goldsmith D, Covic A, Vervloet M et al. Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrol Dial Transplant 2015;30(5):698-700. doi: 10.1093/ndt/gfv050
(check this in PDF content)
6
Li S, Chen YW, Peng Y et al. Trends in parathyroidectomy rates in US hemodialysis patients from 1992 to 2007. Am J Kidney Dis 2011; 57(4): 602–611. doi: 10.1053/j.ajkd.2010.10.041
(check this in PDF content)
7
Akaberi S, Clyne N, Sterner G et al. Temporal trends and risk factors for parathyroidectomy in the Swedish dialysis and transplant population – a nationwide, population-based study 1991 – 2009. BMC Nephrol 2014; 15:75. doi: 10.1186/1471-2369-15-75
(check this in PDF content)
8
Lafrance JP, Cardinal H, Leblanc M. Effect of cinacalcet availability and formulary listing on parathyroidectomy rate trends. BMC Nephrol 2013; 14: 100. doi: 10.1186/1471-2369-14-100
(check this in PDF content)
9
Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int Suppl 2006;(102):S3-7
(check this in PDF content)
10
Герасимчук РП, Кондаков СБ, Земченков АЮ. Коррекция умеренного вторичного гиперпаратиреоза местными инъекциями препаратов витамина D в паращитовидные железы. Нефрология и диализ 2015; 17(1):58-66. [Gerasimchuk RP, Kondakov SB, Zemchenkov AY. The correction of secondary hyperthyroidism by local vitamin D injection in parathyroid glands. Nephrology and Dialysis (in Rus) 2015; 17(1):58-66
(check this in PDF content)
11
Герасимчук РП, Земченков АЮ, Новокшонов КЮ и др. Влияние паратиреоидэктомии на динамику лабораторных показателей МКН ХБП и выживаемость пациентов, получающих заместительную терапию диализом в Санкт-Петербурге. Нефрология и диализ 2016; 18(1):40-49. [Gerasimchuk RP, Zemchenkov AY, Novokshonov KY et al. The impact of parathyroidectomy on the dynamics of CKD-MBD laboratory parameters and survival of dialysis patients in St.-Petersburg. Nephrology and Dialysis (in Rus) 2016; 18(1):40-49]
(check this in PDF content)
12
Герасимчук РП, Земченков АЮ. Влияние местных инъекций препаратов активной формы витамина D в паращитовидные железы под контролем УЗИ на динамику лабораторных показателей МКН ХБП и выживаемость пациентов в сравнении с продолжением медикаментозной терапии. Вестник трансплантологии и искусственных органов 2016; 18(2): [Gerasimchuk RP, Zemchenkov AY. Effect of guided by ultrasound direct vitamin D injections into parathyroid glands on laboratory markers and survival of patients with refractory secondary hyperparathyroidism. Russian Journal of Transplantology and Artificial Organs (in Rus) 2016; 18(2):]
(check this in PDF content)
13
Fritz CO, Morris PE, Richler JJ. Effect size estimates: current use, calculations, and interpretation. J Exp Psychol Gen 2012;141(1):2-18. doi: 10.1037/a0024338
(check this in PDF content)
14
Kelley K, Preacher KJ. On effect size. Psychol Methods 2012;17(2):137-52. doi: 10.1037/a0028086.
(check this in PDF content)
15
Hedges LV. Distribution theory for Glass’ estimator of effect size and related estimators. J of Educational Statistics 1981; 6 (2): 107–128. doi:10.3102/10769986006002107.
(check this in PDF content)
16
Hedges LV. Olkin I. Statistical Methods for Meta-Analysis. Orlando: Academic Press. 1985. ISBN 0-12-336380-2.
(check this in PDF content)
17
Verbitskaya EV. Meta-analysis: Problems with Russian Publications. Int J Risk Saf Med 2015;27 Suppl 1:S89-90. doi: 10.3233/JRS-150702
(check this in PDF content)
18
Grangé S, Hanoy M, Le Roy F et al. Monitoring of hemodialysis quality-of-care indicators: why is it important? BMC Nephrol 2013;14:109. doi: 10.1186/1471-2369-14-109
(check this in PDF content)
19
Kliger AS. Quality Measures for Dialysis: Time for a Balanced Scorecard. Clin J Am Soc Nephrol 2016;11(2):363-368. doi: 10.2215/CJN.06010615
(check this in PDF content)
20
Stivelman JC. Monitoring quality of care at dialysis facilities: a case for regulatory parsimony-and beyond. Clin J Am Soc Nephrol 2012; 7(10): 1673-1681. doi: 10.2215/CJN.01750212
(check this in PDF content)
21
Cunningham J, Floege J, London G et al. Clinical outcomes in secondary hyperparathyroidism and the potential role of calcimimetics. NDT Plus 2008;1(Suppl 1):i29-i35. doi: 10.1093/ ndtplus/sfm042.
(check this in PDF content)
22
Chertow GM, Block GA, Correa-Rotter R et al. EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012;367(26):24822494. doi: 10.1056/NEJMoa1205624
(check this in PDF content)
23
Ballinger AE, Palmer SC, Nistor I et al. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev 2014; 12: CD006254. doi: 10.1002/14651858.CD006254.pub2
(check this in PDF content)
24
Duranton F, Rodriguez-Ortiz ME, Duny Y et al. Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. Am J Nephrol 2013; 37(3): 239-248. doi: 10.1159/000346846
(check this in PDF content)
25
Tominaga Y, Matsuoka S, Uno N, Sato T. Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics. Ther Apher Dial 2008; 12 [Suppl 1]:S21-26. doi: 10.1111/j.17449987.2008.00627.x
(check this in PDF content)
26
NICE: Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. 2007. NICE technology appraisal guidance 117; guidance.nice.org.uk/ta117
(check this in PDF content)
27
Brunkhorst R. Mineral and bone disorder in chronic kidney disease: Critical appraisal of pharmacotherapy. [Article in German] Internist (Berl) 2014; 55(3): 334-339. doi: 10.1007/ s00108-014-3447-4
(check this in PDF content)
28
Кеттелер М, Мартин КД, Вольф М и др. Парикальцитол в сравнении с цинакальцетом в сочетании с низкими дозами витамина D в лечении вторичного гиперпаратиреоза у пациентов на гемодиализе: результаты исследования IMPACT SHPT. Нефрология 2012; 16(4):28-38 [Ketteler M, Martin KJ, Volf M et al. Paricalcitol compared to cinacalcet with low-dose vitamin d therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT research. Nephrology (in Rus) 2012; 16(4):28-38]
(check this in PDF content)
29
Нюйтен М, Рудакова АВ, Маршалл T. Эффективность затрат на парикальцитол и комбинацию цинакальцета и неселективных препаратов витамина D при хронической болезни почек 5д стадии в Российской Федерации. Нефрология 2014; 18(6):64-70 [Nuijten M, Rudakova A, Marshall T. Health economic evaluation of paricalcitol and combination of cinacalcet with nonselective vitamin d in patients with chronic kidney disease 5d stage in Russian Federation. Nephrology (in Rus) 2014; 18(6):64-70]
(check this in PDF content)
30
Boer R, Lalla AM, Belozeroff V. Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States. J Med Econ 2012;15(3):509-520. doi: 10.3111/13696998.2012.664799.
(check this in PDF content)
31
Wetmore JB, Gurevich K, Sprague S et al. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol 2015;10(6):1031-1040. doi: 10.2215/CJN.07050714
(check this in PDF content)
32
Sprague SM, Wetmore JB, Gurevich K et al. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol 2015; 10(6): 1021-1030. doi: 10.2215/CJN.03270314
(check this in PDF content)
33
Yamamoto M, Ogata H, Mizobuchi M et al. Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism. Clin Exp Nephrol 2012; 16(2): 292-299. doi: 10.1007/s10157-011-0547-5
(check this in PDF content)
34
Tominaga Y, Tanaka Y, Sato K et al. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997; 13(2): 78–86.
(check this in PDF content)
35
Tominaga Y, Matsuoka S, Sato T. Clinical features and hyperplastic patterns of parathyroid glands in hemodialysis patients with advanced secondary hyperparathyroidism refractory to maxacalcitol treatment and required parathyroidectomy. Ther Apher Dial 2007;11(4):266-273
(check this in PDF content)
36
Chen J, Zhou QY, Wang JD. Comparison between subtotal parathyroidectomy and total parathyroidectomy with autotransplantation for secondary hyperparathyroidism in patients with chronic renal failure: A meta-analysis. Horm Metab Res 2015; 47(9): 643-651. doi: 10.1055/s-0035-1554689
(check this in PDF content)
37
Герасимчук РП, Новокшонов КЮ, Земченков АЮ. Распространенность, течение и возможности коррекции вторичного гиперпаратиреоза у пациентов на диализе. Клиническая нефрология 2015; 5-6: 48-59 [Gerasimchuk RP, Novokshonov K, Zemchenkov A. Prevalence, course and opportunities for correction of secondary hyperparathyroidism in dialysis patients. Clinical Nephrology (in Rus) 2015; 5-6: 48-59]
(check this in PDF content)
38
Sharma J, Raggi P, Kutner N et al. Improved long-term survival of dialysis patients after near-total parathyroidectomy. J Am Coll Surg 2012; 214: 400–407. doi: 10.1016/j.jamcollsurg.2011.12.046
(check this in PDF content)
39
Hiramitsu T, Tominaga Y, Okada M et al. A Retrospective Study of the Impact of Intraoperative Intact Parathyroid Hormone Monitoring During Total Parathyroidectomy for Secondary Hyperparathyroidism: STARD Study. Medicine (Baltimore) 2015;94(29):e1213. doi: 10.1097/MD.0000000000001213
(check this in PDF content)
40
Ivarsson KM, Akaberi S, Isaksson E. et al. The effect of parathyroidectomy on patient survival in secondary hyperparathyroidism. Nephrol Dial Transplant 2015;30(12):2027-2033. doi: 10.1093/ndt/gfv334
(check this in PDF content)
41
Ishani A, Liu J, Wetmore JB et al. Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol 2015; 10(1): 90-97. doi: 10.2215/ CJN.03520414
(check this in PDF content)
42
Komaba H, Taniguchi M, Wada A et al. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 2015; 88(2): 350-359. doi: 10.1038/ki.2015.72
(check this in PDF content)
43
Lin HC, Chen CL, Lin HS et al. Parathyroidectomy improves cardiovascular outcome in nondiabetic dialysis patients with secondary hyperparathyroidism. Clin Endocrinol (Oxf) 2014; 80(4): 508–515. doi: 10.1111/cen.12333
(check this in PDF content)
44
Goldenstein PT, Elias BM, de Freitas do Carmo LP et al. Parathyroidectomy Improves Survival In Patients with Severe Hyperparathyroidism: A Comparative Study. PLoS One 2013; 8(8): e68870. doi: 10.1371/journal.pone.0068870
(check this in PDF content)
45
Costa-Hong V, Jorgetti V, Gowdak LH et al. Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism. Surgery 2007; 142(5): 699-703
(check this in PDF content)
46
Conzo G, Perna AF, Savica V et al. Impact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to the calcimimetics era. BMC Surg 2013; 13 [Suppl 2]: S4. doi: 10.1186/1471-2482-13-S2-S4
(check this in PDF content)
47
Wetmore JB, Liu J, Do TP et al. Changes in secondary hyperparathyroidism-related biochemical parameters and medication use following parathyroidectomy. Nephrol Dial Transplant 2016;31(1):103-111. doi: 10.1093/ndt/gfv291
(check this in PDF content)
48
Kitaoka M, Fukagawa M, Fukuda N et al. Direct calcitriol injections into enlarged parathyroid glands in chronic dialysis patients with severe parathyroid hyperfunction. Nephrol 1995; 1(6): 563–567
(check this in PDF content)
49
Shiizaki K, Negi Sh, Hatamura I et al. Direct vitamin D injection induces apoptosis of parathyroid cells. Kidney Int 2006; Suppl 70: S12-S15.
(check this in PDF content)
50
Saito A, Matsumoto Y, Oyama Y et al. Effectiveness of weekly percutaneous maxacalcitol injection therapy in patients with secondary hyperparathyroidism. Ther Apher Dial 2010;14(1):98103. doi: 10.1111/j.1744-9987.2009.00706.x
(check this in PDF content)
51
Shiizaki K, Hatamura I, Negi S et al. Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. Kidney Int 2003;64(3):992-1003.
(check this in PDF content)
52
Герасимчук Р, Земченков А, Кондаков С, Медведева Е. Малоинвазивный метод коррекции вторичного гиперпаратиреоза при хронической болезни почек. Врач 2009; 11:15-22. [Gerasimchuk R, Zemchenkov A, Kondakov S, Medvedeva E. Miniinvasive technique in the correction of secondary hyperparathyroidism in chronic renal disease. Vrach (in Rus) 2009; 11:15-22]
(check this in PDF content)
53
Полухина ЕВ, Езерский ДВ. Использование чрескожного введения этанола под контролем ультразвука в лечении вторичного гиперпаратиреоза. Диагностическая и интервенционная радиология 2015; 9(1):11-19 [Polukhina EV, Ezersky DV. Percutaneous ethanol injection therapy under ultrasound guidance as a treatment of secondary hyperparathyroidism Diagnostic and Interventional Radiology (in Rus) 2015; 9(1):11-19]
(check this in PDF content)
54
Ильичева ЕА, Аюшеева АВ, Синицын ВА и др. Хирургическое лечение рецидивного третичного гиперпаратиреоза, вызванного распространенным паратиреоматозом (обзор литературы и клиническое наблюдение). Нефрология и диализ 2015; 17(1):89-99 [Surgical treatment of recurrent tertiary hyperparathyroidism caused by widespread parathyromatosis (Case report and literature review). Nephrology and Dialysis (in Rus) 2015; 17(1):89-99]
(check this in PDF content)
55
Новокшонов КЮ, Карелина ЮВ, Земченков АЮ и др. Результаты скрининга на маркеры минеральных и костных нарушений при хронической болезни почек среди диализных пациентов Северо-Западного Федерального Округа. Нефрология 2016; 20(1):36-50. [Novokshonov KY, Karelina YV, Zemchenkov A et al. Chronic kidney disease mineral and bone disorder markers in screening study among dialysis patients in North-West Federal Region of Russia. Nephrology (in Rus) 2016; 20(1):36-50]
(check this in PDF content)
56
Щеголев АА, Ларин АА, Когут ОБ и др. Ультразвуковой контроль за состоянием паращитовидных желез у больных с терминальной стадией хронической почечной недостаточности. Хирургическая практика 2014; 3:34-37 [Schegolev А А, Larin А А, Коguт ОB. Ultrasonic monitoring of the parathyroid glands in patients with end-stage chronic renal insufficiency. Surgical Practice (in Rus) 2014; 3:34-37]
(check this in PDF content)
57
Егшатян ЛВ, Рожинская ЛЯ, Кузнецов НС, Шамхалова МШ. Плейотропные эффекты паратиреоидэктомии и агониста кальций-чувствительного рецептора цинакалцета. Рациональная фармакотерапия в кардиологии 2013; 9(2):152-157. [Egshatyan LV, Rozhinskaya LYa, Kuznetsov NS, Shamkhalova MSh. Pleiotropic effects of parathyroidectomy and agonist calcium-sensitive receptor, cinacalcet. Rational Pharmacotherapy in Cardiology (in Rus) 2013; 9(2):152-157]
(check this in PDF content)
58
Ветчинникова ОН, Захарова НМ. Лечебная тактика при персистирующем и рецидивирующем вторичном (почечном) гиперпаратиреозе. Клиническая нефрология 2013; 1:53-59. [Vetchinnikova ON, Zakharova NM. Therapeutic tactics in persistent and recurrent secondary (renal) hyperparathyroidism. Clinical Nephrology (in Rus) 2013; 1:53-59]
(check this in PDF content)
59
Самохвалова НА, Майстренко НА, Ромащенко ПН. Программный подход к лечению вторичного гиперпаратиреоза при хронической болезни почек. Вестник хирургии им. И.И. Грекова 2013; 172(2):43-46. [Samohvalova NA, Maystrenko NA, Romashchenko P N. Programmed approach to the treatment
(check this in PDF content)